The NINDS t-PA Stroke Trial: Progress Report
Effective treatment to improve outcome after the onset of acute ischemic stroke continues to be elusive. Interest in thrombolytic therapy as a potential treatment for stroke has undergone a revival coincident with the development of newer agents, such as human recombinant tissue-type plasminogen activator (rt-PA), and better appreciation for the need for rapid treatment within the first minutes to hours after the onset of symptoms .
KeywordsAcute Ischemic Stroke Thrombolytic Therapy Stroke Onset Data Monitoring Committee Stroke Trial
Unable to display preview. Download preview PDF.
- 2.del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA, Wechsler L, Busse O, Greenlee R Jr, Brass L, Mohr JP, Feldmann E, Hacke W, Kase CS, Biller J, Gress D, Otis SM (1992) Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 32: 78–86PubMedCrossRefGoogle Scholar
- 6.Mori E, Yoneda Y, Tabuchi M. Yoshida T, Ohkawa S. Ohsumi Y, Kitano K, Tsutsumi A, Yamadori A (1992) Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 42: 976–982Google Scholar
- 9.Lefkopoulou M. Ryan L (1989) Global tests for multiple binary outcomes. Biometrics 4: 975–988Google Scholar